NRx Pharmaceuticals, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from NRx Pharmaceuticals, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
1/3 · 2/3Sales grew in 1 of the last 3 years; profit grew in 2 of 3.
Steadier than 50% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-44.7×Operating cash was negative last year, while some debt falls due within a year.
Lower than 71% of Healthcare companies in United States.
Cash Cushion Ratio
+7%Cash, after subtracting all debt, equals 7% of its market value (net cash).
Lower than 54% of Healthcare companies in United States.
Tangible Assets Ratio
79%Of every $100 the company owns, $79 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 52% of Healthcare companies in United States.
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
NRx Pharmaceuticals, Inc. made a loss over the last year. NRx Pharmaceuticals, Inc. owes $1.00 for every $1 it owns. NRx Pharmaceuticals, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossNRx Pharmaceuticals, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
-611.23NRx Pharmaceuticals, Inc.'s book value is negative (it owes more than it owns), so P/B is not meaningful.
Market cap
$104 MThe total market value of all of NRx Pharmaceuticals, Inc.'s shares at today's price (share price × number of shares), smaller than 65% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
NegativeNRx Pharmaceuticals, Inc.'s net worth is negative ($0 M below zero, balance sheet 30 Jun 2026): it owes more than it owns, so book value per share and P/B are not meaningful.
Owes vs Owns
1.00×NRx Pharmaceuticals, Inc. owes $1.00 for every $1 it owns, so it owes more than it owns, higher than 86% of Healthcare companies in United States.
Dividend yield
NoneNRx Pharmaceuticals, Inc. does not currently pay a dividend.
Profit growth
LossNRx Pharmaceuticals, Inc. made a loss in each of the last two years.
Profit margin
-2336.5%NRx Pharmaceuticals, Inc. lost $2336 for every $100 of revenue.
Interest cover
Not coveredNRx Pharmaceuticals, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashNRx Pharmaceuticals, Inc. held $7 M more cash than debt (net cash) at Dec 2025.
Questions
How much does NRx Pharmaceuticals, Inc. owe compared with what it owns?
NRx Pharmaceuticals, Inc. owes $1.00 for every $1 it owns, so it owes more than it owns, higher than 86% of Healthcare companies in United States.
Does NRx Pharmaceuticals, Inc. pay a dividend?
No. NRx Pharmaceuticals, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.